Humoral Response to SARS-CoV-2 mRNA Vaccination in Nephrology Patients Receiving Immunosuppressive Therapy (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0680; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Regimens included glucocorticoids (GKS), rituximab/cyclophosphamide, calcineurin inhibitors, mycophenolate mofetil, azathioprine, and combinations thereof. Participants received mRNA vaccines available in Poland during the study period: BNT162b2 (Comirnaty) or mRNA-1273 (Spikevax)...Conclusion Immunosuppressive therapy is associated with weaker humoral response and higher non-response rates after mRNA SARS-CoV-2 vaccination. These data support risk-adapted vaccination strategies and closer post-vaccination monitoring in immunosuppressed nephrology patients."
Clinical • Infectious Disease • Nephrology • Novel Coronavirus Disease • Renal Disease • Respiratory Diseases • Vasculitis
|
|
Ewa Kotwica-Strzalek; Stanislaw Niemczyk
|